ICMJE DISCLOSURE FORM

Date:13-March-2023
Your Name:Xuwen Yang
Manuscript Title:Worldwide prevalence, risk factors and burden of chronic cough in the general population: a
narrative review
Manuscript number (if known):JTD-22-1435-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5		None	

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None		
7	Support for attending meetings and/or travel	None		
	meetings and/or travel			
8	Patents planned, issued or pending	None		_
	pending			_
9	Participation on a Data	None		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	None		
	in other board, society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment,	None		
	materials, drugs, medical writing, gifts or other services			
13	Other financial or non-	None		
	financial interests			
				_
	ase summarize the above co	nflict of interest in the foll	owing box:	
1 *			1	

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:13-March-2023	
Your Name:Kian Fan Chung	
Manuscript Title:Worldwide prevalence, risk factors and burden of chro	nic cough in the general population: a
narrative review	
Manuscript number (if known):JTD-22-1435-R2	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	GSK	Payment to institution
	any entity (if not indicated	Merck	Payment to institution
	in item #1 above).	UKRI	Payment to institution
3	Royalties or licenses	None	

4	Consulting fees	GSK, Merck, AZ, Roche	Advisory Board meetings. Payment to self
		Reckitt, Shionogi	Advisory Board meeting, Payment to self.
5	Payment or honoraria for	GSK	To self
	lectures, presentations,	Merck	To self
	speakers bureaus,	AstraZeneca	To self
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
7	Company for all 1	Navas	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	Nocion	Payment to self
9	Safety Monitoring Board or	Novartis, BI	Payment to self
	Advisory Board	Novartis, Di	rayment to sen
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or	None	
	non-financial interests		

Please summarize the above conflict of interest in the following box:

Kian Fan Chung has received grants from GSK, Merck, and UKRI, consulting fees from GSK, Merck, AZ, Roche, Reckitt, and Shionogi, and honoraria from GSK, Merck, and AstraZeneca. He has participated in advisory board for Nocion, Novartis and BI.

Please place an "X" next to the following statement to indicate your agreement:
X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:13-March-2023
Your Name:Kewu Huang
Manuscript Title:Worldwide prevalence, risk factors and burden of chronic cough in the general population: a
narrative review
Manuscript number (if known):JTD-22-1435-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	the National Natural Science Foundation of China (81870032) the 'Summit' Talent Training Program, Beijing Hospital Authority (DFL20190301)	It had no role in the writing or submission of the manuscript. It had no role in the writing or submission of the manuscript.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

None Speakers bureaus, manuscript writing or educational events None		Г	T	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None				
speakers bureaus, manuscript writing or educational events 6	5	Payment or honoraria for	None	
speakers bureaus, manuscript writing or educational events 6				
manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 10 Stock or stock options None				
educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
None				
testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Avone None	_		News	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None	6	I	None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None		testimony		
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None				
meetings and/or travel Patents planned, issued or pending	7	Support for attending	None	
8 Patents planned, issued or pending				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None Participation on a Data None None None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None None None None		go arra, or traver		
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None Participation on a Data None None None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None None None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None Participation on a Data None None None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None None None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None Participation on a Data None None None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None None None None				
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options None Participation on a Data None None None Receipt of equipment, materials, drugs, medical writing, gifts or other services None None None None None None	8	Patents planned issued or	None	
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		Pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None				
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None None None None	9		None	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- None None None None		Safety Monitoring Board or		
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None		Advisory Board		
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options None None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	10	Leadership or fiduciary role	None	
committee or advocacy group, paid or unpaid 11 Stock or stock options None None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None		I		
group, paid or unpaid 11 Stock or stock options None None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None				
11 Stock or stock options None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonNoneNoneNone				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	11	Stock or stock options	None	
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None				
materials, drugs, medical writing, gifts or other services 13 Other financial or non- None None	12	Receipt of equipment.	None	
writing, gifts or other services 13 Other financial or non- None None				
services 13 Other financial or non- None None				
13 Other financial or non- None None				
financial interests	13		None	
		financial interests		
				<u>. </u>

Please summarize the above conflict of interest in the following box:

Dr. Huang reports that this study was supported by the National Natural Science Foundation of China (No. 81870032
to Kewu Huang) and the 'Summit' Talent Training Program, Beijing Hospital Authority (No. DFL20190301 to Kewu
Huang).

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.